Company reported clinically meaningful, dose-dependent improvements in ADHD symptoms with its investigational drug ALKS 7290. The treatment was well tolerated with no serious adverse effects, and the company is advancing to phase II studies. Year-to-date stock performance is strong at +57.9%.
Articles that tag ALKS but are mainly about other companies.
Current market leader with VIVITROL (naltrexone) holding highest market share in 2025. However, projected to lose market dominance by 2036 as newer therapies like AD04 gain approval, indicating declining competitive position.
The court approval moves the acquisition forward as planned, but this is a routine procedural step. The sentiment is neutral as it represents expected progress on a previously announced transaction rather than new positive or negative information about Alkermes' business.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
